Short Interest Summary: Biopharmx Corporation (NYSEMKT:BPMX) Shorted Shares Decreased By 66.42%

November 28, 2016 - By Clifton Ray   ·   0 Comments

Short Interest Summary: Biopharmx Corporation (NYSEMKT:BPMX) Shorted Shares Decreased By 66.42%

The stock of Biopharmx Corporation (NYSEMKT:BPMX) registered a decrease of 66.42% in short interest. BPMX’s total short interest was 41,300 shares in November as published by FINRA. Its down 66.42% from 123,000 shares, reported previously. With 191,600 shares average volume, it will take short sellers 0 days to cover their BPMX’s short positions. The short interest to Biopharmx Corporation’s float is 0.17%. The stock increased 4.62% or $0.012 on November 25, hitting $0.274. Biopharmx Corp (NYSEMKT:BPMX) has declined 70.47% since April 25, 2016 and is downtrending. It has underperformed by 76.49% the S&P500.

BioPharmX Corporation is a specialty pharmaceutical company. The company has a market cap of $9.43 million. The Firm is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter products that address markets in women’s health and dermatology. It currently has negative earnings. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

BPMX Company Profile

BioPharmX Corporation, incorporated on April 24, 2014, is a specialty pharmaceutical company. The Firm is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. The Company’s platform technologies include delivery mechanisms for molecular iodine (I2) and antibiotics. The Firm focuses on developing products that treat health or age-related conditions, including which are not being addressed or treated or, which are treated with drug therapies or drug delivery approaches that are sub-optimal. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. The molecular iodine project includes an OTC dietary supplement version or VI2OLET, for the alleviation of symptoms of FBC, as well as a prescription drug version for the treatment of moderate to severe, periodic breast pain associated with FBC and cyclic mastalgia.

More notable recent Biopharmx Corp (NYSEMKT:BPMX) news were published by: Streetinsider.com which released: “Form S-1MEF BioPharmX Corp” on November 22, 2016, also Prnewswire.com with their article: “BioPharmX Corporation Announces Closing Of $4.3 Million Public Offering” published on April 01, 2016, Prnewswire.com published: “BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its …” on March 18, 2015. More interesting news about Biopharmx Corp (NYSEMKT:BPMX) were released by: Thestreet.com and their article: “BioPharmX (BPMX) Stock Soars on Potential ‘Breakthrough’ Acne Treatment” published on December 14, 2015 as well as 247Wallst.com‘s news article titled: “BioPharmX Prices Secondary Offering” with publication date: March 29, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Clifton Ray


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>